GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » EBITDA Margin %

Paion Ag (Paion Ag) EBITDA Margin % : -102.94% (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Paion Ag's EBITDA for the six months ended in Jun. 2023 was $-7.57 Mil. Paion Ag's Revenue for the six months ended in Jun. 2023 was $7.36 Mil. Therefore, Paion Ag's EBITDA margin for the quarter that ended in Jun. 2023 was -102.94%.


Paion Ag EBITDA Margin % Historical Data

The historical data trend for Paion Ag's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag EBITDA Margin % Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -453.80 -115.09 9.85 -264.10 12.96

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -219.83 -309.73 47.91 -96.99 -102.94

Competitive Comparison of Paion Ag's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paion Ag's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Paion Ag's EBITDA Margin % falls into.



Paion Ag EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Paion Ag's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=4.566/35.22
=12.96 %

Paion Ag's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-7.572/7.356
=-102.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion Ag  (OTCPK:PAIOF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Paion Ag EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Paion Ag's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.